DARE
What one share of Dare Bioscience holds
Pharmaceutical Preparations
The terms “we,” “us,” “our,” “Daré” or the “Company” refer collectively to Daré Bioscience, Inc. and its wholly-owned subsidiaries, unless otherwise stated or the context otherwise requires. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.
Dare Bioscience’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.10 |
|---|---|
| Profit | −$0.78 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$0.83 |
| Cash and investments | $0.83 |
| Book value | −$0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.81 | $0.64 | −$1.09 | — | −$0.78 |
| 2018 | — | −$1.56 | $0.00 | −$0.96 | — | $0.59 |
| 2019 | — | −$0.97 | $0.00 | −$0.85 | — | $0.02 |
| 2020 | — | −$0.91 | $0.00 | −$0.84 | — | −$0.03 |
| 2021 | — | −$0.63 | $0.00 | −$0.47 | — | $0.46 |
| 2022 | — | −$0.37 | $0.00 | −$0.21 | — | $0.13 |
| 2023 | — | −$4.15 | $0.09 | −$5.43 | — | −$0.61 |
| 2024 | $0.00 | −$0.48 | $0.07 | $0.58 | — | −$0.69 |
| 2025 | $0.09 | −$1.20 | $0.03 | −$0.92 | — | $0.20 |